Chevallard Daniel R. 4
4 · Viracta Therapeutics, Inc. · Filed Nov 28, 2023
Insider Transaction Report
Form 4
Chevallard Daniel R.
Chief Executive Officer
Transactions
- Sale
Common Stock
2023-11-28$0.50/sh−3,720$1,860→ 98,822 total - Exercise/Conversion
Restricted Stock Units
2023-11-25−6,889→ 41,333 total→ Common Stock (6,889 underlying) - Exercise/Conversion
Common Stock
2023-11-25+6,889→ 102,542 total
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
- [F2]The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
- [F3]One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.